Summary A low concentration of differentiation inducers such as dimethylsulphoxide (DMSO), sodium butyrate, hexamethylene bisacetamide and sodium phenylacetate greatly enhanced the antiproliferative effect in vitro and in vivo of interferon a (IFN-a) to several human lung adenocarcinoma cells. The agents induced morphological changes in the adenocarcinoma cells and the agents together with IFN-a-induced alkaline phosphatase activity, which is a typical marker of type II pneumocyte maturation. To understand the mechanism of the DMSO-enhanced interferon sensitivity, we examined the effect of DMSO on high-affinity IFN-a receptor and interferon-stimulated promoter-binding factors. The lung adenocarcinoma cells were not impaired in IFN-a receptor and interferon-stimulated gene transactivation factor 3 (ISGF-3). Our data suggest that the enhancement of interferon sensitivity in the lung adenocarcinoma cells acts downstream of the activation of ISGF-3.
Lung cancer survival remains poor, with approximately 13% a 5 year survival in 1993 (Ginsberg et al., 1993) . The most active drugs so far have been cis-platinum (II) diamine dichloride (CDDP) (Loether and Einhorn, 1984) , vindesine (Klastersky et al., 1983) , vinblastin, mitomycin C and ifosphamide (Worrall, 1982) in the chemotherapy of nonsmall-cell lung cancer. The overall response rate is in the range 20-30% with 3-5% complete responses (Donnadieu et al., 1991) . The current treatment results from non-smallcell lung cancer clearly call for improved therapy.
The degree of differentiation is an important prognostic factor in many tumours. Induction of differentiation is closely linked to loss of tumorigenicity, and differentiation inducers can block the phenotypic expression of malignant cells. The use of all-trans retinoic acid in the treatment of patients with acute promyelocytic leukaemia has shown that differentiation therapy can lead to a predictable clinical remission (Huang et al., 1988; Degos, 1990; Ohno et al., 1993) . However, administration of differentiation inducer alone in experimental therapy of solid tumours has produced only low remission rates. Furthermore, differentiation induction of solid tumours is not always an irreversible process. These b findings call for other strategies, such as combination of differentiation induction with chemotherapy, radiotherapy and/or immunotherapy. Induction of differentiation alters the properties of leukaemia and embryonal carcinoma cells, such as sensitivities to chemotherapeutic drugs (Okabe-Kado et al., 1986; Honma et al., 1991; Okabe-Kado et al., 1991; Guchelaar et al., 1993) . We previously reported that treatment with haemin, an inducer of erythroid differentiation, greatly increased the sensitivity of human myeloid leukaemia K562 cells to 1-fl-D-arabinofuranosyl cytosine (Honma et al., 1991; Okabe-Kado et al., 1986) , and that erythroid differentiation factor (activin A) enhanced the sensitivity of multidrug-resistant leukaemia cells to vincristine, actinomycin D and doxorubicin (Okabe-Kado et al., 1991) .
In order to find a rational combination of differentiation and chemotherapy on lung carcinoma, we characterise in this al., 1988; McCormick et al., 1995) . Cells were washed twice with cold PBS, resuspended to a cell density of 107 cells ml-1 of cold distilled water and sonicated for 10 s. The reaction mixture contained 50 mM glycinesodium hydroxide (pH 10.5) and 0.5 mm magnesium chloride, 4.2 mM p-nitrophenyl phosphate, and the cell lysate in a total volume of 0.4 ml. The incubation was allowed to proceed for 60 min at 37°C and then the reaction was stopped by the addition of 1 ml of 0.1 M sodium hydroxide. The absorbance of p-nitrophenol was determined at 410 nm for calculation of the enzyme activity (Koyama and Ono, 1976 
Gel mobility shift assay
The synthetic double-stranded oligonucleotides corresponding to the sequence -113 to -74 of human 2-5 (A)-synthetase gene (Rutherford et al., 1988) containing the interferonstimulated response element (ISRE) region was synthesised in a DNA synthesiser (Applied Biosystem model 392). The sequences of the oligonucleotides were 5'-gCTCCTCCCT- (Figure 2 ). IFN-a did not essentially induce enzyme activity in PC9 cells either, but the combined treatment with DMSO and IFN-ax greatly induced alkaline phosphatase activity in the cells (Figure 2) . Next, we examined effects of the differentiation inducers on the sensitivity to anti-cancer drugs. Treatment with DMSO did not essentially affect sensitivity of the human lung carcinoma cells to CDDP, VP-16, doxorubicin or 5-FU (data not shown). Similar results were obtained when the cells were treated with butyrate, HMBA or phenylacetate. However, the sensitivity to IFN-a of adenocarcinoma PC9 cells was greatly enhanced by treatment with a low concentration of DMSO and the enhancing effect of DMSO was dose-dependent ( Figure 3) . Growth of PC9 cells was not inhibited by treatment with a high concentration of IFN-ct alone (IC50>6.0x l04 IU ml-%), while growth of 1% (128 mM) DMSO-treated PC9 cells was effectively inhibited by IFN-a (IC50 = 3.0 x 103 IU ml-'). In the case of Lu65 cells, IC50s of IFN-a alone and IFN-a plus DMSO were 2.4 x 104 and 1.4 x 102 IU ml-' respectively, indicating that DMSO enhances 170 times the sensitivity to IFN-a (Table I ). The other lung carcinoma cell lines, PC14, Lu65, Lu99 and Lu135, were also sensitive to the combined treatment with DMSO and IFN-a, but not to IFN-a alone. With respect to growth inhibition, lung adenocarcinoma ABC-1 and PC7 cells were highly sensitive to IFN-a alone, whereas H69 cells were resistant to even the combined treatment with DMSO and IFN-a (Table I) . Similar results were obtained when PC9 cells were treated with sodium butyrate, phenylacetate or HMBA instead of DMSO (Figure 4 ). The treatment with IFN-a in the presence of DMSO or butyrate was effective in inhibiting growth of PC9, PC14, Lu65, Lu99 and Lu135 cells, but HMBA and phenyl acetate were less effective in Lu65 (Figure 4 ) and Lu135 cells (data not shown). In Lu99 cells, the sensitising effect of DMSO was relatively weak (Figure 3 and Table I ), but butyrate and phenyl acetate were the most (Figure 4) , suggesting that the enhancement by differentiation inducers varies from different carcinoma cells. The effect of the time addition of DMSO or IFN-a on the growth inhibition was examined. Figure 5 shows that 4 day pretreatment with IFN-a significantly affects the growthinhibitory activity of DMSO plus IFN-ax on treatment for the last 3 days, suggesting that delayed addition of DMSO is effective. On the contrary, the delayed addition of IFN-a was not so effective in growth inhibition. These results suggest that continuous treatment with IFN-a is essential to evoke the synergistic effect with DMSO and IFN-a.
The effect of continuous treatment with 1% DMSO and 600 IU ml-' IFN-a added simultaneously on proliferation of PC9 cells was examined for 12 days. The cell density was kept (Figure 7b ), whereas the viable cells were evident all over the control tissues (Figure 7a) . Observations of the gross morphology of the tumours excised after treatment showed not only a significant difference in size but also a marked reduction in blood supply, judging by the whiter appearance of the tumour. al., 1988) . Then we examined the activation of ISGF-3, which is involved in the activation of IFN-oc-stimulated genes, in DMSO-treated PC9 cells. PC9 cells were cultured with 1000 IU ml-' IFN-a and 1% DMSO for 2.5 h, and nuclear extracts were prepared and used for the gel shift mobility assay of ISGF-3 (Figure 8 ). Nuclear extracts that were preincubated with anti-ISGF-3 antibody showed super-shift moving ( Figure 8a , lane 2) and addition of an excess of unlabelled probe eliminated the band of ISFG-3 complex (Figure 8a , lane 3). Addition of unlabelled non-specific DNA competitor (AP-1) had no effect (data not shown). These results indicate that the binding reaction is specific to ISGF-3. Next, we treated with 0.5-2% DMSO for 2.5 -48 h and examined the effect of DMSO on ISGF-3 binding activity in PC9 cells. Figure 8b shows that ISGF-3 activity in PC9 cells is not essentially affected by DMSO, suggesting that the ISGF signalling system is effective in untreated PC9 cells. ISREs (Levy et al., 1988 , 1989 Dale et al., 1989) . Only one of the three well-characterised ISRE-binding factors, ISGF-3, seems to be directly responsible for the transcriptional activation of ISGs (Levy et al., 1989) . A lack of response towards IFN-a has been attributed to an impaired activation of transcription factor ISGF-3 in the case of IFN-resistant lymphocytic leukaemia cells Xu et al., 1994) . However, as revealed by gel mobility shift assays, DMSO-treated (IFN-a-sensitive) Retinoic acid is a potent inducer of myeloid leukaemia and the only agent that is clinically used in differentiation therapy of acute leukaemia (Degos, 1990; Ohno et al., 1993 ). Lippman et al. (1992a demonstrated that the combination of 13-cis-retinoic acid and IFN-a was highly active in the treatment of patients with advanced squamous cell carcinomas of skin and uterine cervix, although the combination treatment was virtually inactive in patients with advanced non-small-cell lung cancer (Arnold et al., 1994) . Retinoic acid did not essentially affect the sensitivity of lung cancer cells to IFN-a in our experiments (data not shown).
DMSO, an industrial solvent, caused partial or total disappearance of experimentally induced amyloid deposits in mice (Hanai et al., 1979) , and therapeutic trials on patients with amyloidosis indicated that prolonged treatment with DMSO may be effective in certain types of systemic amyloidosis (Isobe et al., 1976; Iwasaki et al., 1994) . DMSO treatment induced a dramatic reduction in pulmonary infiltration in a patient with IgG multiple myeloma and no serious side-effect of DMSO was encountered (Iwasaki et al., 1994) . Therapy of HMBA, another polar compound that is more potent than DMSO in inducing differentiation of murine erythroleukaemia cells (Reuben et al., 1976) , had some success in clinical trials against certain cancers (Young et al., 1988) . These results suggest that DMSO and HMBA in combination with IFN-a are useful in treatment with some lung cancer patients. However, DMSO and HMBA are not ideal drug prospects. From the extensive structure-activity relations developed in testing many compounds, it seem likely that we obtain more useful sensitising compounds in treatment with IFN-cx of lung cancer patients. This is a promising approach to lung cancer therapy, potentially without many of the disadvantages of cytotoxic agents.
